| Identification | Back Directory | [Name]
Curcumin β-D-Glucuronide | [CAS]
227466-72-0 | [Synonyms]
Curcumin Impurity 7
Curcumin β-D-Glucuronide
Curcumin β-D-Glucuronide
Curcumin b-D-Glucuronide
Curcumin-4-O-β-D-glucuronide
Curcumin 4-O-β-D-glucuronide
Curcumin-4-O-beta-D-glucuronide min. 85%
Curcumin β-D-Glucuronide
DISCONTINUED. Please see C838505.
4-[(1E,6E)-7-(4-Hydroxy-3-Methoxyphenyl)-3,5-dioxo-1,6-heptadien-1-yl]-2-Methoxyphenyl β-D-Glucopyranosiduronic Acid
β-D-Glucopyranosiduronic acid, 4-[(1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxo-1,6-heptadien-1-yl]-2-methoxyphenyl
(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[4-[(1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenoxy]oxane-2-carboxylicaci
(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[4-[(1E,6E)-7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenoxy]oxane-2-carboxylic acid | [Molecular Formula]
C27H28O12 | [MDL Number]
MFCD28963761 | [MOL File]
227466-72-0.mol | [Molecular Weight]
544.5 |
| Chemical Properties | Back Directory | [Boiling point ]
838.7±65.0 °C(Predicted) | [density ]
1.470±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
powder | [pka]
2.78±0.70(Predicted) | [color ]
Orange |
| Hazard Information | Back Directory | [Chemical Properties]
Dark Orange Solid | [Uses]
Curcumin β-D-Glucuronide is a metabolite of Curcumin (C838510) in hepatic tissue and portal blood. | [Definition]
ChEBI: Curcumin glucuronide is a diarylheptanoid. | [Biological Activity]
Studies have demonstrated th at Curcumin β-D-glucuronide exhibits anticancer properties in mouse tumor models and human metastatic colorectal cancer cell lines by promoting apoptosis. Additionallyit has shown potential as a colon cancer prevention agent through metabolism by r at liver microsomes. This compound also possesses anti-inflammatory attributes attributed to its ability to inhibit prostaglandin E2 (PGE2) levels in humans. | [in vivo]
Curcumin-β-D-glucuronide (90 mg/kg; i.p. thrice a week for 3 weeks) exhibit potent anti-tumor effects on KRASm/TP53w HCT116 xenograft model[1]. | Animal Model: | Female BALB/c/AnNCr j‐nu/nude mice (6 weeks) were transplanted KRASm/TP53w HCT116 cells[1] | | Dosage: | 90 mg/kg | | Administration: | I.p. thrice a week for 3 weeks | | Result: | Suppressed tumor growth by 38%.
Did not show a negative impact on body weight.
Attenuated NF‐κB activity.
|
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|